Allogene Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and …
Allogene Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and … Presented Initial Phase 1 UNIVERSAL Trial Data on ALLO-715 at The American Society of Hematology (ASH) Meeting Providing First Proof-of-Concept for an AlloCAR T™ Therapy in Relapsed/Refractory Multiple Myeloma Updated ALLO-501 and Initial ALLO-501A AlloCAR T Data in Non-Hodgkin Lymphoma (NHL) Planned […]
Read More